A Toll-like Receptor-Activating, Self-Adjuvant Glycan Nanocarrier
The global pandemic of COVID-19 highlights the importance of vaccination, which remains the most efficient measure against many diseases. Despite the progress in vaccine design, concerns with suboptimal antigen immunogenicity and delivery efficiency prevail. Self-adjuvant carriers–vehicles that can...
Main Authors: | Daping Xie, Yiming Niu, Ruoyu Mu, Senio Campos de Souza, Xiaoyu Yin, Lei Dong, Chunming Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Chemistry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2022.864206/full |
Similar Items
-
Toll-like receptor agonists as cancer vaccine adjuvants
by: Donghwan Jeon, et al.
Published: (2024-12-01) -
Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases
by: Jing-Xing Yang, et al.
Published: (2022-02-01) -
A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines
by: Kishore R. Alugupalli, et al.
Published: (2024-05-01) -
Safety and efficacy of toll-like receptor agonists as therapeutic agents and vaccine adjuvants for infectious diseases in animals: a systematic review
by: Harriet Oboge, et al.
Published: (2024-09-01) -
Differential Foreign Body Reactions between Branched and Linear Glucomannan Scaffolds
by: Yuwei Li, et al.
Published: (2022-12-01)